LivaNova (LIVN) to Release Earnings on Wednesday

LivaNova (NASDAQ:LIVN - Get Free Report) will release its earnings data before the market opens on Wednesday, May 1st. Analysts expect LivaNova to post earnings of $0.47 per share for the quarter. LivaNova has set its FY 2024 guidance at 2.950-3.050 EPS and its FY24 guidance at $2.95-3.05 EPS.Persons interested in listening to the company's earnings conference call can do so using this link.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company's revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period last year, the firm posted $0.81 earnings per share. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LivaNova Stock Performance

Shares of LIVN traded up $0.92 during mid-day trading on Wednesday, reaching $55.94. 977,319 shares of the company's stock were exchanged, compared to its average volume of 614,870. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The stock has a market capitalization of $3.02 billion, a PE ratio of 174.82 and a beta of 0.89. The business's fifty day simple moving average is $53.92 and its 200-day simple moving average is $50.59. LivaNova has a 52-week low of $42.75 and a 52-week high of $59.86.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on LIVN shares. Mizuho reissued a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a research note on Wednesday, March 27th. StockNews.com cut shares of LivaNova from a "buy" rating to a "hold" rating in a research note on Wednesday, April 17th. Robert W. Baird boosted their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a "neutral" rating in a research note on Thursday, February 22nd. Barclays boosted their price objective on shares of LivaNova from $57.00 to $61.00 and gave the company an "equal weight" rating in a research note on Monday, February 26th. Finally, Needham & Company LLC restated a "buy" rating and set a $72.00 target price on shares of LivaNova in a research report on Wednesday, March 20th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, LivaNova has a consensus rating of "Hold" and an average price target of $64.40.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.